These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 31682829)

  • 1. Taking Subvisible Particle Quantitation to the Limit: Uncertainties and Statistical Challenges With Ophthalmic Products for Intravitreal Injection.
    Gühlke M; Hecht J; Böhrer A; Hawe A; Nikels F; Garidel P; Menzen T
    J Pharm Sci; 2020 Jan; 109(1):505-514. PubMed ID: 31682829
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Processing Impact on Monoclonal Antibody Drug Products: Protein Subvisible Particulate Formation Induced by Grinding Stress.
    Gikanga B; Eisner DR; Ovadia R; Day ES; Stauch OB; Maa YF
    PDA J Pharm Sci Technol; 2017; 71(3):172-188. PubMed ID: 27789805
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of compounded bevacizumab prepared for intravitreal injection.
    Yannuzzi NA; Klufas MA; Quach L; Beatty LM; Kaminsky SM; Crystal RG; D'Amico DJ; Kiss S
    JAMA Ophthalmol; 2015 Jan; 133(1):32-9. PubMed ID: 25233052
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Backgrounded Membrane Imaging (BMI) for High-Throughput Characterization of Subvisible Particles During Biopharmaceutical Drug Product Development.
    Helbig C; Ammann G; Menzen T; Friess W; Wuchner K; Hawe A
    J Pharm Sci; 2020 Jan; 109(1):264-276. PubMed ID: 30914272
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmaceutical feasibility of sub-visible particle analysis in parenterals with reduced volume light obscuration methods.
    Hawe A; Schaubhut F; Geidobler R; Wiggenhorn M; Friess W; Rast M; de Muynck C; Winter G
    Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt B):1084-7. PubMed ID: 23454051
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Biopharmaceutical Industry Perspective on the Control of Visible Particles in Biotechnology-Derived Injectable Drug Products.
    Mathonet S; Mahler HC; Esswein ST; Mazaheri M; Cash PW; Wuchner K; Kallmeyer G; Das TK; Finkler C; Lennard A
    PDA J Pharm Sci Technol; 2016; 70(4):392-408. PubMed ID: 27091885
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Variance Between Different Light Obscuration and Flow Imaging Microscopy Instruments and the Impact of Instrument Calibration.
    Matter A; Koulov A; Singh S; Mahler HC; Reinisch H; Langer C; Zucol B; Mathaes R
    J Pharm Sci; 2019 Jul; 108(7):2397-2405. PubMed ID: 30844365
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Semi-Quantitative Analysis of Inherent Visible Particles for Biopharmaceutical Products.
    Cash PW; Narwal R; Levitskaya SV; Krause S; Murphy D; Mazaheri M
    PDA J Pharm Sci Technol; 2016; 70(2):134-42. PubMed ID: 26797974
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Subvisible (2-100 μm) particle analysis during biotherapeutic drug product development: Part 2, experience with the application of subvisible particle analysis.
    Corvari V; Narhi LO; Spitznagel TM; Afonina N; Cao S; Cash P; Cecchini I; DeFelippis MR; Garidel P; Herre A; Koulov AV; Lubiniecki T; Mahler HC; Mangiagalli P; Nesta D; Perez-Ramirez B; Polozova A; Rossi M; Schmidt R; Simler R; Singh S; Weiskopf A; Wuchner K
    Biologicals; 2015 Nov; 43(6):457-73. PubMed ID: 26324466
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Analyzing subvisible particles in protein drug products: a comparison of dynamic light scattering (DLS) and resonant mass measurement (RMM).
    Panchal J; Kotarek J; Marszal E; Topp EM
    AAPS J; 2014 May; 16(3):440-51. PubMed ID: 24570341
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Multicompany Assessment of Submicron Particle Levels by NTA and RMM in a Wide Range of Late-Phase Clinical and Commercial Biotechnology-Derived Protein Products.
    Hubert M; Yang DT; Kwok SC; Rios A; Das TK; Patel A; Wuchner K; Antochshuk V; Junge F; Bou-Assaf GM; Cao S; Saggu M; Montrond L; Afonina N; Kolhe P; Loladze V; Narhi L
    J Pharm Sci; 2020 Jan; 109(1):830-844. PubMed ID: 31647951
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Contribution of Intravenous Administration Components to Subvisible and Submicron Particles Present in Administered Drug Product.
    Pollo M; Mehta A; Torres K; Thorne D; Zimmermann D; Kolhe P
    J Pharm Sci; 2019 Jul; 108(7):2406-2414. PubMed ID: 30849460
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Application of a Best Practice Approach Using Resonant Mass Measurement for Biotherapeutic Product Characterization.
    Krueger AB; Hadley J; Cheney PP; Markova N; Carpenter JF; Fradkin AH
    J Pharm Sci; 2019 May; 108(5):1675-1685. PubMed ID: 30599170
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mixing monoclonal antibody formulations using bottom-mounted mixers: impact of mechanism and design on drug product quality.
    Gikanga B; Chen Y; Stauch OB; Maa YF
    PDA J Pharm Sci Technol; 2015; 69(2):284-96. PubMed ID: 25868994
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mechanistic Investigation on Grinding-Induced Subvisible Particle Formation during Mixing and Filling of Monoclonal Antibody Formulations.
    Gikanga B; Hui A; Maa YF
    PDA J Pharm Sci Technol; 2018; 72(2):117-133. PubMed ID: 29030532
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Application of Tunable Resistive Pulse Sensing for the Quantification of Submicron Particles in Pharmaceutical Monoclonal Antibody Preparations.
    Stelzl A; Schneid S; Winter G
    J Pharm Sci; 2021 Nov; 110(11):3541-3545. PubMed ID: 34303672
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biopharmaceutical evaluation of surface active ophthalmic excipients using in vitro and ex vivo corneal models.
    Juretić M; Cetina-Čižmek B; Filipović-Grčić J; Hafner A; Lovrić J; Pepić I
    Eur J Pharm Sci; 2018 Jul; 120():133-141. PubMed ID: 29702232
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Subvisible Particle Analysis of 17 Monoclonal Antibodies Approved in China Using Flow Imaging and Light Obscuration.
    Guo S; Yu C; Guo X; Jia Z; Yu X; Yang Y; Guo L; Wang L
    J Pharm Sci; 2022 Apr; 111(4):1164-1171. PubMed ID: 34551350
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Collaborative Study for Analysis of Subvisible Particles Using Flow Imaging and Light Obscuration: Experiences in Japanese Biopharmaceutical Consortium.
    Kiyoshi M; Shibata H; Harazono A; Torisu T; Maruno T; Akimaru M; Asano Y; Hirokawa M; Ikemoto K; Itakura Y; Iwura T; Kikitsu A; Kumagai T; Mori N; Murase H; Nishimura H; Oda A; Ogawa T; Ojima T; Okabe S; Saito S; Saitoh S; Suetomo H; Takegami K; Takeuchi M; Yasukawa H; Uchiyama S; Ishii-Watabe A
    J Pharm Sci; 2019 Feb; 108(2):832-841. PubMed ID: 30121316
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Formulation strategies and particle engineering technologies for pulmonary delivery of biopharmaceuticals.
    Cun D; Wan F; Yang M
    Curr Pharm Des; 2015; 21(19):2599-610. PubMed ID: 25876915
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.